Mode of administration of dulaglutide: Implications for treatment adherence

Patient Preference and Adherence

Volumn 10, Issue , 2016, Pages 975-982

  Amblee, Ambika ^a,b  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Patient treatment satisfaction; Quality of life; Treatment satisfaction; Type 2 diabetes; Weekly GLP1

Indexed keywords

DULAGLUTIDE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; PLACEBO;

AGE; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; GENDER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SELF INJECTION; TREATMENT DURATION;

EID: 84975263399     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S82866     Document Type: Review

References (40)

1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
2. Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17(11):1065–1074.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336.
6. Albert NM. Improving medication adherence in chronic cardiovascular disease. Crit Care Nurse. 2008;28(5):54–64.
7. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and health care cost. Med Care. 2005;43(6):521–530.
8. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74–109.
9. Picha KM, Cunningham MR, Drucker DJ, et al. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes. 2008;57(7):1926–1934.
10. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26(4):287–296.
11. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434–438.
12. Chien JY, Cui S, Chaudhary A, Loghin C. LY2189265, a long-acting glucagon-like peptide-1 analog does not affect gastric emptying of acetaminophen after multiple dosing in healthy subjects. Diabetes. 2010;59:Suppl 1:Abs 600-P.
13. Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(5):426–433.
14. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dula for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29(10):1260–1267.
15. Umpierrez GE, Blevins T, Rosenstock J, et al; EGO Study Group. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13(5):418–425.
16. Skrivanek Z, Gaydos BL, Chien JY, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014;16(8):748–756.
17. Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: Analyses of data from clinical trials. Clin Pharmacokinet. 2016;55(5):625–634.
18. Trulicity (dulaglutide) product information. Available from: http://uspl.lilly.com/trulicity/trulicity.html#pi. Accessed December 10, 2015.
19. Trulicity (dulaglutide) instructions for use. Available from: http://uspl.lilly.com/trulicity/trulicity.html#ug. Accessed December 10, 2015.
20. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–1357.
21. Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849–858.
22. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241–2249.
23. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057–2066.
24. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159–2167.
25. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168–2176.
26. Emoto M, Terauchi Y, Ozeki A, Oura T, Takeuchi M, Imaoka T. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocr J. 2015;62(12):1101–1114.
27. Dungan KM, Raz I, Skrivanek Z, Sealls W, Fahrbach JL. Achieving the composite endpoint of HbA1c<7.0%, no weight gain, and no hypoglycaemia in the once weekly dulaglutide AWARD program. Diabetes Obes Metab. 2016;18(1):49–55.
28. Grunberger G, Forst T, Fernández Landó L, et al. Early fasting glucose measurements can predict later glycemic response to once weekly dulaglutide. Diabet Med. 2016;33(3):391–394.
29. Gurung T, Shyangdan DS, O’Hare JP, Waugh N. A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. Diabetes Metab Syndr Obes. 2015;8:363–386.
30. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731–737.
31. Ferdinand KC, Botros FT, Atisso CM, Sager PT. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016;15:38.
32. Raibouaa A, Borgeke H, Alexiou D, Lowin J, Norrbacka K. Cost-effectiveness of dulaglutide 1.5 mg once weekly for the treatment of patients with type two diabetes mellitus in Sweden. Value Health. 2015;18(7):A607.
33. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31:213–224.
34. Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:882–892.
35. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33:240–245.
36. Reaney M, Yu M, Lakshmanan M, Pechtner V, van Brunt K. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17(9):896–903.
37. Van Brunt K, Reaney M, Yu M, Lakshmanan M, Curtis B, Mitchell B. Patient-reported outcomes with dula, exenatide, or placebo (AWARD-1). In: Proceedings of the 49th European Association for the Study of Diabetes (EASD) Annual Meeting; 2013; Barcelona, Spain. Abstract 985.
38. A Randomized, open-label, parallel-arm, noninferiority comparison of the effects of two doses of LY2189265 and insulin glargine on glycemic control in patients with type 2 diabetes on stable doses of metformin and glimepiride (AWARD-2). Available from: ClinicalTrails.gov. ClinicalTrials.gov Identifier: NCT01075282. Accessed November 20, 2015.
39. The impact of LY2189265 versus insulin glargine in combination with insulin lispro for the treatment to target of type 2 diabetes mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes-4). Available from: ClinicalTrails.gov. ClinicalTrials.gov Identifier: NCT01191268. Accessed November 20, 2015.
40. Matfin G, Van Brunt K, Zimmermann AG, Threlkeld R, Ignaut DA. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9(5):1071–1079.